Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGaA Drops Parkinson’s Treatment Sarizotan

This article was originally published in The Pink Sheet Daily

Executive Summary

Disappointing Phase III trial results led to the decision.

You may also be interested in...



Merck Serono Extends CNS Collaboration With Newron, Invests In Israel

Merck Serono's revised deal with Newron gives the latter a license to develop two additional compounds, with Merck holding a buy-back option.

Merck Serono Extends CNS Collaboration With Newron, Invests In Israel

Merck Serono's revised deal with Newron gives the latter a license to develop two additional compounds, with Merck holding a buy-back option.

Merck KGaA Buys Serono, Gaining U.S. Commercial Organization

Merck acquires family-owned shares representing 64.5% of Serono's capital and will launch a tender offer for the remainder, at a total value of $13.27 bil.

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel